JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm expects a “messy” Q1 report for Eylea but sees the company’s setup improving throughout 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Biotech Alert: Searches spiking for these stocks today
- Regeneron, Sanofi announce Dupixent authorization in Japan
- Regeneron: Positioned for Growth Amidst Challenges with a Promising Pipeline and Catalyst-Rich Future
- BMO says Eylea court decision ‘modest negative’ for Regeneron
- Eylea biosimilar injunction denial ‘negative’ for Regeneron, says UBS